960216-36-8

Upstream product

• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 173336-76-0 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene 
• 37942-01-1 5-bromo-2-methoxyphenol 
• 621-59-0 isovanillin 

Downstream Products

• 960216-40-4 (R)-2-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-3-methyl-butyric acid benzyl ester 
• 960216-52-8 (E)-(S)-5-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-6-methyl-hept-2-enoic acid ethyl ester 
• 960216-48-2 (S)-3-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-4-methyl-pentanoic acid ethyl ester 
• 960216-50-6 (S)-3-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-4-methyl-pentan-1-ol 
• 960216-46-0 (S)-3-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-4-methyl-pentanenitrile 
• 960216-42-6 (R)-2-[4-methoxy-3-(3-methoxy-propoxy)-phenoxy]-3-methyl-butan-1-ol 
• 960216-44-8 4-((R)-1-bromomethyl-2-methyl-propoxy)-1-methoxy-2-(3-methoxy-propoxy)-benzene 

Relevant academic research and scientific papers

HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR

Disclosed in the present invention is a new 11-oxo-7,11-dihydro-6h-benzo-[f]pyrido[1,2-d][1,4]azepine oxepin-10-carboxylic acid derivative serving as a hepatitis B virus surface antigen inhibitor. Specifically disclosed are a compound represented by formula (V) or a pharmaceutically acceptable salt thereof, and applications of the compound represented by formula (V) or the pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof in the treatment of viral hepatitis B.

NOVEL OXA-AND AZA-TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

Provided herein are oxa- and aza-tricyclic 4-pyridone-3-carboxylic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for inhibiting HBsAg secretion and HBV DNA production, and for treatment and/or prophylaxis of hepatitis B infection.

PYRROLIDINE COMPOUNDS AS RENIN INHIBITORS

Novel 3,4-di-, 3,3,4-di-, 3,4.4,-tri- and 3,3,4,4-tetra-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I) wherein the substituents are as described in the specification.